Issues in production of viral gene transfer vectors. Stefan Kochanek Department of Gene Therapy Ulm University
|
|
- Anna McCarthy
- 6 years ago
- Views:
Transcription
1 Issues in production of viral gene transfer vectors Stefan Kochanek Department of Gene Therapy Ulm University
2 Only few positive results in gene therapy so far - many early phase, few late phase clinical trials - only approved gene therapy products - based on adenovirus Gendicine Shenzen Sibiono GeneTech Co. (2003) Oncorine H101 Shanghai Sunway Biotech Co. (2005)... and availabe only in China
3 Most frequently used viral vectors Adenovirus (double stranded DNA) Adeno-Associated Virus (single stranded DNA) Retrovirus (single stranded RNA)
4 Some comparisons... Route of application Adeno - episomal in vivo AAV - episomal in vivo Retro/Lenti - integrating ex vivo (mainly)
5 Some comparisons... Route of application Needed amounts per dose (VP) in humans Adeno - episomal in vivo >10 14 AAV - episomal in vivo >10 14 Retro/Lenti - integrating ex vivo (mainly) >10 9 (i.u.)
6 Some comparisons... Route of application Needed amounts per dose (VP) in humans Production yield/cell (VP) Adeno - episomal in vivo > AAV - episomal in vivo > Retro/Lenti - integrating ex vivo (mainly) >10 9 (i.u.) (i.u.) High cell numbers needed for production of the product
7 Adenovirus vectors Adenovirus (double stranded DNA) Genome Vectors - double stranded DNA - mostly had5 based - also other human serotypes (vaccine) - also from other species (vaccine) Use - tumor therapy, genetic vaccine (in vivo)
8 Production of adenovirus vectors 293 cells - academic institutions PER.C6 - industry
9 293 cells: generation of replication competent adenovirus (RCA) In 293 cells: through homologous recombination between vector and cellular DNA 293 cellular DNA E1 E1-deleted vector!e1 RCA ITR " E1 ITR
10 PER.C6 cells: no generation of RCA In PER.C6 cells: no homologous recombination between vector and cellular DNA PER.C6 cellular DNA E1 E1-deleted vector!e1
11 Very rare events in PER.C6 at large scale production Heterologous recombination events may rarely lead to helperdependent E1-positive region containing viral particle (HDEP) Murakami et al. 2004
12 Overall Production/cell lines cave RCA PER.C6 - industry standard Purification CsCl Chromatography - academic units - industry Storage Different buffers/freezing Quality control Assays well established Reference material (ARMWG) available
13 Overall Production/cell lines cave RCA PER.C6 - industry standard Purification CsCl Chromotagraphy - academic units - industry Storage Different buffers/freezing Quality control Assays well established Reference material (ARMWG) available field is quite mature, but...
14 Production is not the real problem Route of application Required amounts per dose (VP) in humans for liver transduction Production yield/cell (VP) Adeno in vivo > consider - a human liver has 1.5 x cells - human body about cells
15 Production is not the problem Route of application Required amounts per dose (VP) in humans for liver transduction Production yield/cell (VP) Adeno in vivo > consider - a human liver has 1.5 x cells - human body about cells Efficacy is very low! Why?
16 Efficacy is low because of many barriers - Interaction with cellular and non-cellular compartments CAR on Erys, Complement activation, Receptor issues... anti-ad antibodies, serum proteins anti-ad cellular immune response blood vessel issues/basement membrane extracellular matrix - Physical issues (diffusion, pressure) -... To get adenovirus to work we need to work on the virus
17 AAV-based vectors Adeno-Associated Virus Genome Size Use Promising - Single-stranded or double stranded DNA genome - 20 nm - genetic diseases (in vivo) - many different serotypes with different tropism
18 Genetic map of AAV ITR p5 p p ITR RNAs polya 4.2 kb Rep kb Rep kb Rep kb Rep kb VP1 2.3 kb VP2 2.3 kb VP3 3 functions needed for production ITR origin of replication, packaging signal Rep proteins replication Cap (VP 1-3) capsid proteins
19 AAV production systems 1. Stable rep/cap cell line (HeLa) - infection with 2 viruses a) Adeno WT b) Adeno-AAV vector 2. Helper-free transfection method (293, 293-T) - transfection 3 plasmids a) AAV packaging plasmid (rep/cap) b) AAV vectors c) Adenovirus plasmid (E2A, E4, VA) 3. Stable rep/cap + vector cell line (HeLa) - infection with 1 virus a) Adeno WT 4. HSV-based system (Vero, BHK) - infection 2 viruses a) HSV-rep/cap b) HSV-AAV vector 5. Baculovirus-based system (SF9) - infection with 2 to 3 viruses a) Baculo rep b) Baculo cap c) Baculo AAV vector
20 Production based on 3 different Baculoviruses
21 Advantages/disadvantages of the baculovirus system Advantages - cells derived from insects - safety - scalable system Disadvantages - stability of Baculovirus during amplification
22 Helper-virus free production method Needed a) vector plasmid b) rep/cap plasmid c) Ad helper plasmid (E2A, VA, E4)
23 Advantages/disadvantages of the transfection system Advantages - no virus involved Disadvantages - limitation in scale up
24 Overall Production/cell lines different Purification CsCl/iodixanol Chromatography - depending on system - academic units - industry Quality control Assays established Reference material (ARMWG) available (AAV2, AAV8) field is developing well, but...
25 field is developing well, but... still very large amounts of vector are needed one reason the relatively high particle/i.u. ratio (>100) while AAV wildtype has a low particle/i.u. ratio needed is a better understanding of the reasons for the differences in biology/infectivity of AAV wildtype versus AAV vector
26 Conclusions on viral vectors Vector systems at different levels of development Very high cell numbers for production required due to - low in vivo activity: Adenovirus, AAV - low production yield: Retro/lentivirus Adenovirus AAV - production overall quite mature cells only at small scale (RCA) - PER.C6 well developed (industry standard) minor issues with HDEPs - strategies to overcome barriers a/o achieve specific gene transfer are essential - developing fast, many serotypes - plasmid transfection at smaller scale for some areas (e.g. eye) - scale-up is still an issue with room for improvements - improving infectivity (particle/i.u.ratio) of vectors would be a major advance Retro/lentivirus - developing fast/many clinical trials - room for improvements for up- and downstream
Manufacturing Viral Gene Therapy Vectors: General Approaches and Challenges John T. Gray
Manufacturing Viral Gene Therapy s: 1 Dr. Vice President, Research & Development Audentes Therapeutics, Inc. San Francisco, USA Natural virus life cycle Late Early Viral Virally infected cell Naïve cell
More informationQuality Control Assays
QUALITY CONTROL An integral part of the Penn Vector Core is its robust quality control program which is carried out by a separate quality control group. Quality control assays have been developed and optimized
More informationThe Molecular Virology Support Core: Adenoviral Vectors and Beyond
The : Adenoviral Vectors and Beyond Christoph A. Kahl, Ph.D. Viral Vector Workshop, May 5th, 2011 Outline 1) Overview of the MVSC 2) Adenoviral Vectors 3) Expertise and Services Overview What does the
More informationVECTOR SAFETY INFORMATION. AAV Vectors: Material Information
VECTOR SAFETY INFORMATION AAV Vectors: Material Information AAV vectors contain recombinant transgene sequences (e.g. encoding reporter or therapeutic genes) flanked by the AAV inverted terminal repeats
More informationG0202 pfbaavmcsbghpa MCS. Red type indicates unique restriction site. Plasmid Features:
G0202 pfbaavmcsbghpa Plasmid Features: Coordinates Feature 183-348 Tn7L 377-617 SV40pA Complementary 678-818 AAV2 ITR (141bp) 820-975 MCS 976-1189 BgHpA 1243-1372 AAV2 ITR (130bp) 1929-2462 Gentamicin
More informationRed type indicates unique restriction site. Antibiotic Resistance: Ampicillin and Gentamicin Bacterial Backbone: pfastbac (Invitrogen)
G0619 pfbaavmcscmvegfp SV40pA Plasmid Features: Coordinates Feature 194-348 Tn7L 376-511 SV40pA (complementary-remnant of pfb cloning) 678-818 AAV2 ITR (141bp) 877-969 MCS 970-1549 CMV Promoter 1569-2288
More informationMultiple cloning site between CAG and wild type IRES:
G0747 pfbaavcagmcs wtiresegfpbghpa Plasmid Features: Coordinates Feature 194-348 Tn7L 376-511 SV40pA Complementary 678-818 AAV2 ITR (141bp) 938-2607 CAG promoter 872-955 mcs 2687-3273 wtires (11th ATG
More informationBaculovirus Adenovirus Adeno-associated virus Lentivirus/Retrovirus Many more: Vaccinia virus, Semliki Forest virus
Recombinant Viruses Viruses produced by recombinant DNA technology Naturally occuring recombinant virus (= when more than one virus strain infects the same cell and genetic information is exchanged) Common
More informationComparability Is Not a Nightmare, Just Think Ahead!
Comparability Is Not a Nightmare, Just Think Ahead! Margarida Menezes Ferreira Senior Assessor at INFARMED PT expert at BWP/CHMP - EMA member of the CAT - EMA (margarida.menezes@infarmed.pt) I attend this
More informationLecture 7 Adeno-associated viral vectors
Lecture 7 Adeno-associated viral vectors Viral vectors, continued 19th November 2012 AAV adenovirus 2 Infectious cycle of AAV 3 Adeno-associated viruses AAV Small, non-pathogenic single stranded DNA viruses.
More informationComparing Droplet Digital PCR to Quantitative PCR: Evolving the Gene Therapy Viral Vector Analytical Paradigm
Comparing Droplet Digital PCR to Quantitative PCR: Evolving the Gene Therapy Viral Vector Analytical Paradigm Jarrod Dean Principal Research Associate, Analytical Development Sanofi Presented by GTC, a
More informationAntibiotic Resistance: Ampicillin and Gentamicin Bacterial Backbone: pfastbac (Invitrogen)
G01066 pfbaavmcswtiresmcherrybghpa Plasmid Features: Coordinates Feature 194-348 Tn7L 377-617 SV40pA Complementary 678-818 AAV2 ITR (141bp) 860-955 mcs 956-1542 wtires 1543-2253 mcherry 2268-2481 BgHpA
More informationAdeno-Associated Viral (AAV) Vectors. Biosafety office
Adeno-Associated Viral (AAV) Vectors Biosafety office April 2014 Copyright 2014 University of Cincinnati, All Rights Reserved. All rights reserved. No part of this publication may be reproduced, distributed,
More informationAntibiotic Resistance: Ampicillin and Gentamicin Bacterial Backbone: pfastbac (Invitrogen)
G01067 pfbaavcagmcswtiresmcherrybghpa Plasmid Features: Coordinates Feature 194-348 Tn7L 377-617 SV40pA Complementary 678-818 AAV2 ITR (141bp) 938-2607 CAG 2600-2685 mcs 2687-3273 wtires 3274-3984 mcherry
More information10/07/2018. Liver directed gene therapy. - An overview. DNA/RNA therapies for Wilson s disease. The liver, organ of choice. Highly vascularised
DNA/RNA therapies for Wilson s disease Julien Baruteau - Great Ormond Street Institute of Child Health, University College London, UK Metabolic Medicine, Great Ormond Street Hospital, London, UK PLAN Landscape
More informationVECTOR SYSTEMS. Vector Systems
VECTOR SYSTEMS Vector Systems The vector systems currently available through Penn Vector Core are those derived from adenoassociated virus (AAV), adenovirus and lentivirus. The Core offers AAV-based vectors
More informationJ. Fraser Wright, Ph.D.
Towards Better Characterization of Recombinant AAV Gene Transfer Vectors: Case Studies Illustrating Challenges with Dose Determining Vector Concentration methods J. Fraser Wright, Ph.D. Well Characterized
More informationAAVanced Concentration Reagent
AAVanced Concentration Reagent Catalog # AAV100A-1, AAV110A-1 A limited-use label license covers this product. By use of this product, you accept the terms and conditions outlined in the Licensing and
More information2017 Well Characterized Biological Products
2017 Well Characterized Biological Products Gene Therapy Treatments for Hemophilia A & B Process Validation Considerations in the Manufacturing of Gene Therapy Products Robert Baffi, Ph.D., MBA Executive
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationUpdate from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017
Update from the Center for Biologics Evaluation and Research (CBER) Peter Marks, M.D., Ph.D. GMP By The Sea 2017 Outline Products regulated Significance of complex biologics Product and process Cutting
More informationThe Elite Provider. Cell & Gene. Therapy Manufacturing
The Elite Provider Cell & Gene Therapy Manufacturing GMP Manufacturing Services The cgmp manufacturing in Vigene is compliant with US FDA and EU EMA regulatory requirements. The manufacturing area consists
More informationUNDERSTANDING GENE REPLACEMENT THERAPY FOR GENETIC DISEASES
UNDERSTANDING GENE REPLACEMENT THERAPY FOR GENETIC DISEASES What is a genetic disease? A genetic disease is caused by a nonworking or missing gene or genes. A genetic disease can be passed down from one
More informationICH Considerations. Oncolytic Viruses September 17, 2009
INTERNATIONAL CONFERENCE ON HARMONISATION OF TECHNICAL REQUIREMENTS FOR REGISTRATION OF PHARMACEUTICALS FOR HUMAN USE ICH Considerations Oncolytic Viruses September 17, 2009 1. Introduction Oncolytic viruses
More informationReport from the CAT expert meeting
16 March 2018 EMA/CAT/60852/2018 Inspections, Human Medicines Pharmacovigilance and Committees Division Report from the CAT expert meeting Scientific and regulatory considerations for adeno-associated
More informationGene Therapy: The Basics. Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University
Gene Therapy: The Basics Mark A. Kay MD PhD Dennis Farrey Family Professor Stanford University Definition of gene therapy Gene therapy is the introduction of nucleic acids (e.g. DNA/genes) into somatic
More informationInvestigating Critical Challenges in the Gene Therapy Field
Investigating Critical Challenges in the Gene Therapy Field Mapping out the Landscape & Discussing Future Strategies Sander van Deventer Managing Partner Forbion Capital Partners CSO and General Manager
More informationGlobal Leader in Viral Vector Technologies
Global Leader in Viral Vector Technologies Gene Therapy Vaccines - Discovery 1 SIRION BIOTECH ANY GENE TO ANY CELL Expert for viral vectors Competitive proprietary viral vector platforms High-end enabling
More informationcgmp Cell & Gene Therapy
Updated Edition cgmp Cell & Gene Therapy AAV, Adenovirus, and Lentivirus PD and Production Handbook Vigene - the cgmp Viral Vector Experts Table of Contents Vigene cgmp overview... 3 Vigene manufacturing
More informationManufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective
Manufacturing Challenges with Cell and Gene Therapy Products: A Health Canada Perspective CASSS CMC Summer Forum 2017 Chris Storbeck, PhD Health Canada Outline Health Canada organization Regulation of
More informationUniversity of Lethbridge GUIDELINES FOR USE OF ADENO-ASSOCIATED VIRAL VECTORS (AAV VECTORS)
GUIDELINES FOR USE OF ADENO-ASSOCIATED VIRAL VECTORS (AAV VECTORS) Abstract All laboratories using AAV vectors must adhere to this code of practice December 2013 Purpose: To provide guidelines for safely
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) <DRAFT>
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use London, 17 November 2005 Doc. Ref. EMEA/273974/2005 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) NOTE
More informationICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada
ICH Considerations on Viral/Vector Shedding; and Overview of Gene Therapy Activity in Canada Anthony Ridgway, Ph.D. Senior Regulatory Scientist Biologics & Genetic Therapies Directorate Health Canada Open
More informationNaNoplasmid TM. Platform SIZE MATTERS SMALLER IS BETTER
Nanoplasmid TM Platform NaNoplasmid TM The Nanoplasmid is a dramatically improved Key Cassette (
More informationHemophilia and Gene Therapy
Hemophilia and Gene Therapy Jackie Chu June 4, 2008 Overview Hemophilia, the disease Gene therapy Hemophilia as a target for gene therapy Gene delivery systems Clinical trials New methods Future of gene
More informationRecombinant protein production in Eukaryotic cells. Dr. W. McLaughlin BC35C
Recombinant protein production in Eukaryotic cells Dr. W. McLaughlin BC35C Recombinant protein production in Eukaryotic cells! rhuman protein must be identical to the natural protein! Prokaryotes are generally
More informationICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008
European Medicines Agency October 2009 EMEA/CHMP/ICH/607698/2008 ICH Considerations Oncolytic Viruses ONCOLYTIC VIRUSES (EMEA/CHMP/ICH/607698/2008) TRANSMISSION TO CHMP November 2008 TRANSMISSION TO INTERESTED
More informationCRN 18-mo progress update
CRN 18-mo progress update Gene transfer studies for cystinosis Principal investigator: Vasiliki Kalatzis, Ph.D. Co-investigator: Eric J. Kremer, Ph.D. Affiliation: Institut Génétique Moléculaire de Montpellier
More informationAAV-1 Helper Free Packaging System
Product Manual AAV-1 Helper Free Packaging System Catalog Number VPK-401 1 kit FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Adeno-associated viruses (AAVs) are derived from defective
More informationAAV-6 Helper Free Expression System
Product Manual AAV-6 Helper Free Expression System Catalog Number VPK-410-SER6 1 kit FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Adeno-associated viruses (AAVs) are derived
More informationAAV-3 Helper Free Promoterless Expression System
Product Manual AAV-3 Helper Free Promoterless Expression System Catalog Number VPK-411-SER3 1 kit FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Adeno-associated viruses (AAVs)
More informationAAV-5 Helper Free Promoterless Expression System
Product Manual AAV-5 Helper Free Promoterless Expression System Catalog Number VPK-411-SER5 1 kit FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Adeno-associated viruses (AAVs)
More informationTarget Selection in the area of Gene Therapy Harald Petry, PhD
Target Selection in the area of Gene Therapy Harald Petry, PhD Chief Scientific Officer Forward-looking statements This presentation contains forward-looking statements that involve substantial risks and
More informationReference Materials for Adeno-Associated Viruses
Reference Materials for Adeno-Associated Viruses : Recommendations of the Quality Control Sub-Committee John Chiorini (NIH-NIDCR) Paul Husak (Cell Genesys) Gabrielle Kroener-Lux (Progen) James Marich (Cell
More informationAAV-2 Helper Free Expression System
Product Manual AAV-2 Helper Free Expression System Catalog Number VPK-410-SER2 1 kit FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Adeno-associated viruses (AAVs) are derived
More informationICH CONSIDERATIONS Oncolytic Viruses
European Medicines Agency Pre-authorisation Evaluation of Medicines for Human Use 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 ICH CONSIDERATIONS Oncolytic Viruses 20 November 2008 EMEA/CHMP/GTWP/607698/2008
More informationInitial recombinant AAV production system
AAV vectors Initial recombinant AAV production system Construction of plasmids encoding raav genomes in which wild-type sequences necessary for genome replication and packaging (i.e., the AAV ITRs) frame
More informationAAV-3 Helper Free shrna Expression System (GFP)
Product Manual AAV-3 Helper Free shrna Expression System (GFP) Catalog Number VPK-413-SER3 1 kit FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Adeno-associated viruses (AAVs)
More informationAAV-4 Helper Free shrna Expression System (GFP)
Product Manual AAV-4 Helper Free shrna Expression System (GFP) Catalog Number VPK-413-SER4 1 kit FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Adeno-associated viruses (AAVs)
More informationAAV-6 Helper Free shrna Expression System (GFP)
Product Manual AAV-6 Helper Free shrna Expression System (GFP) Catalog Number VPK-413-SER6 1 kit FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Adeno-associated viruses (AAVs)
More informationRecombinant Adeno- Associated Virus (raav) Delivered shrna. - A Technical Guide
Efficient Gene Knockdown via Recombinant Adeno- Associated Virus (raav) Delivered shrna - A Technical Guide Revision 201602.01 ViGene Biosciences 2016 RESEARCH USE ONLY. Not for use in diagnostic procedures
More informationMutagenesis and Expression of Mammalian Clotting Factor IX. Mark McCleland The Children s Hospital of Philadelphia and Lycoming College
Mutagenesis and Expression of Mammalian Clotting Factor IX Mark McCleland The Children s Hospital of Philadelphia and Lycoming College Hemophilia B X-linked blood clotting disorder characterized by a deficiency
More informationAAVpro Titration Kit (for Real Time PCR) Ver.2
Cat. # 6233 For Research Use AAVpro Titration Kit (for Real Time PCR) Ver.2 Product Manual Table of Contents I. Description... 4 II. Components... 6 III. Storage... 6 IV. Materials Required but not Provided...
More informationG0796 pacad5tretightmcssv40pa
G0796 pacad5tretightmcssv40pa Plasmid Features: 6009bp Coordinates Feature ITR: 16-118 Ad5 wt 16-365 and 1240-3698 TRE-tight: 402-717 SV40: 802-1239 Ampicillin: 5806-4946 Antibiotic Resistance: Ampicillin
More informationAAVpro Extraction Solution
Cat. # 6235 For Research Use AAVpro Extraction Solution Product Manual Table of Contents I. Description... 4 II. Components... 4 III. Storage... 4 IV. Materials Required but not Provided... 4 V. Protocol...
More informationAdenovirus upstream and downstream processing. Dr. Mats Lundgren GE Healthcare Life Sciences
Adenovirus upstream and downstream processing Dr. Mats Lundgren GE Healthcare Life Sciences Introduction Viral Vectors Number of 2016 active trials clinical phases globally 170 Clinical trials by main
More informationAAVpro Helper Free System
For Research Use Cat. # 6230, 6650-6657, 6668, 6669, 6673 AAVpro Helper Free System Product Manual For China/Korea/India/Europe Table of Contents I. Description... 4 II. Components... 7 III. IV. Storage...13
More informationFDA Perspectives On Viral & Vector Shedding Studies. Daniel Takefman, Ph.D. Chief, Gene Therapy Branch FDA/CBER ICH Workshop: October 31, 2007
FDA Perspectives On Viral & Vector Shedding Studies Daniel Takefman, Ph.D. Chief, Gene Therapy Branch FDA/CBER ICH Workshop: October 31, 2007 Overview Define shedding studies Outline basis for need of
More informationpaav-rc6 Vector CATALOG NUMBER: VPK-426 STORAGE: -20ºC QUANTITY AND CONCENTRATION: 10 µg at 0.25 µg/µl in TE
Product Data Sheet paav-rc6 Vector CATALOG NUMBER: VPK-426 STORAGE: -20ºC QUANTITY AND CONCENTRATION: 10 µg at 0.25 µg/µl in TE Background Adeno-associated viruses (AAVs) are derived from defective parvoviruses,
More informationStanford University, School of Medicine, Departments of Pediatrics and Genetics, 300 Pasteur Drive, Stanford, California, 94305, USA
Current Gene Therapy, 2003, 3, 281-304 281 From Virus Evolution to Vector Revolution: Use of Naturally Occurring Serotypes of Adeno-associated Virus (AAV) as Novel Vectors for Human Gene Therapy D. Grimm
More informationPotent and durable RNAi mediated suppression of Hepatitis B Virus infection in a mouse model by a nonviral Closed Ended Linear DNA (CELID) vector
Potent and durable RNAi mediated suppression of Hepatitis B Virus infection in a mouse model by a nonviral Closed Ended Linear DNA (CELID) vector November 11, 2018 Dr. Peter W. Roelvink Senior Director
More informationCellular and Gene Therapy Products - CBER Update
DEPARTMENT OF HEALTH AND HUMAN SERVICES CENTER FOR BIOLOGICS EVALUATION and RESEARCH Cellular and Gene Therapy Products - CBER Update Well Characterized Biological Products January 12-14, 2009 Kimberly
More information5.14. GENE TRANSFER MEDICINAL PRODUCTS FOR HUMAN USE. Recombinant vectors Gene transfer medicinal products for human use
EUROPEAN PHARMACOPOEIA 6.0 5.14. Gene transfer medicinal products for human use 01/2008:51400 corrected 6.0 5.14. GENE TRANSFER MEDICINAL PRODUCTS FOR HUMAN USE This general chapter is published for information.
More informationSV40pA. Plasmid Features: Antibiotic Resistance: Ampicillin Backbone: pbr322
G1072 pacad5cagmcswtiresmcherry- SV40pA Plasmid Features: Coordinates Feature ITR: 16-118 Ad5: 16-368 and 897-3361 CAG 441-2112 MCS: 2121-2177 wtires 2179-2769 mcherry 2765-3475 SV40pA: 3484-3923 Ampicillin:
More informationPre-made expression Adenovirus product manual
Pre-made expression Adenovirus product manual Catalog# Product Name Amounts AVP001 RFP adenovirus AVP002 AVP004 AVP005 AVP011 AVP012 AVP017 AVP010 AVP013 AVP014 AVP015 AVP016 AVP-Null AVP001-PBS AVP002-PBS
More informationQuickTiter Adenovirus Titer ELISA Kit
Product Manual QuickTiter Adenovirus Titer ELISA Kit Catalog Number VPK-110 2 x 96 assays FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Recombinant adenoviruses have tremendous
More informationViral Delivery Guide. Choosing the right viral vector for your research
Viral Delivery Guide Choosing the right viral vector for your research OVERVIEW Transfection, the introduction of foreign DNA or RNA into eukaryotic cells, is an indispensable tool for studying gene expression
More informationAAV-2 Helper Free Bicistronic Expression System (Puro)
Product Manual AAV-2 Helper Free Bicistronic Expression System (Puro) Catalog Number VPK-415-SER2 1 kit FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Adeno-associated viruses
More informationPlasmid Features: Coordinates Feature Ad5: and mcmv: MCS: SV40: Ampicillin: (Complimentary)
G0688 pacad5cmvmcssv40pa Plasmid Features: 6210bp Coordinates Feature Ad5: 16-368 and 1441-3899 mcmv: 385-907 MCS: 913-1002 SV40: 1003-1470 Ampicillin: 6007-5147 (Complimentary) Antibiotic Resistance:
More informationThe 5 end problem. 3 5 Now what? RNA primers. DNA template. elongate. excise primers, elongate, ligate
1 2 3 DNA Replication Viruses must replicate their genomes to make new progeny This always requires expression of at least one virus protein, sometimes many (hence always delayed after infection) DNA is
More informationViral vector production for cell and gene therapy
Viral vector production for cell and gene therapy Rénald Gilbert PhD Team Lead : Viral vector Production Director (interim): Vaccines & Immunotherapeutics Program NRC Montreal 6100 Avenue Royalmount Montreal
More informationAAVpro Helper Free System
For Research Use Cat. # 6230, 6652, 6655 AAVpro Helper Free System Product Manual For USA Table of Contents I. Description... 4 II. Components... 6 III. Storage... 9 IV. Materials Required but not Provided...
More informationGenetics and Genomics in Medicine Chapter 9 Questions
Genetics and Genomics in Medicine Chapter 9 Questions Multiple Choice Questions Question 9.1 Which, if any, of the following can be classified as a type of augmentation therapy? a) Treatment using a small
More informationGene Therapy for Hemophilia A: Are we really getting better?
Gene Therapy for Hemophilia A: Are we really getting better? XXIV Congresso Nazionale SISET Novembre 10, 2016 Abano Terme Valder R. Arruda The Children s Hospital of Philadelphia University of Pennsylvania
More informationPre-existing anti-viral vector antibodies in gene therapy
Pre-existing anti-viral vector antibodies in gene therapy Impact on assays, study conduct and data interpretation Mark N Milton, Executive Director DMPK-Bx, Novartis AAPS NBC, May 2016 Gene Therapy Treatment
More informationREGISTRATION DOCUMENT FOR RECOMBINANT DNA RESEARCH
EHRS Date Received: Reg. Doc. No.: REGISTRATION DOCUMENT FOR RECOMBINANT DNA RESEARCH Principal Investigator: Penn ID#: Position Title: School: Department: Mailing Address: Mail Code: Telephone: FAX: E-mail:
More informationIn order to tick one or several possibilities, please use crosses (meaning x or X) into the space provided as (.)
PART 1 (COUNCIL DECISION 2002/813/EC) SUMMARY NOTIFICATION INFORMATION FORMAT FOR THE RELEASE OF GENETICALLY MODIFIED ORGANISMS OTHER THAN HIGHER PLANTS IN ACCORDANCE WITH ARTICLE 11 OF DIRECTIVE 2001/18/EC
More informationNew proposal from the EC:
New proposal from the EC: Gene therapy medicinal product means a biological medicinal product which has the following characteristics: a. it contains an active substance which contains or consists of a
More informationAAV, Adenovirus and Lentivirus-based Gene Delivery Handbook
CMYK C: 73% M:5% Y:31% K:0% C: 49% M:41% Y:41% K:5% Pantone Coated Pantone 319C Pantone Cool Gray 9C AAV, Adenovirus and Lentivirus-based Gene Delivery Handbook MP With cg T Rand CA section Table of Contents
More informationUpdate from the Center for Biologics Evaluation and Research (CBER): Advancing the Development of Complex Biologic Products
Update from the Center for Biologics Evaluation and Research (CBER): Advancing the Development of Complex Biologic Products Peter Marks, M.D., Ph.D. FDLI 2017 Outline Products regulated Significance of
More informationRegistration Document For Biohazards
Protocol #: Registration Document For Biohazards All applicants are required to complete the following sections: Principal Investigator Information Location of Study Section A: General Administrative Information
More informationG1059 pacad5mcswtiresmcherry SV40pA
G1059 pacad5mcswtiresmcherry SV40pA Plasmid Features: 6958bp Coordinates Feature ITR: 16-118 Ad5: 16-368 and 2189-4647 MCS: 375-456 wtires 445-1031 mcherry 1032-1742 SV40pA: 1751-2188 Ampicillin: 6755-5895
More informationRecombinant AAV Vector Reference Standard Stock (RSS)
Recombinant AAV Vector Reference Standard Stock (RSS) Richard O. Snyder University of Florida History Initiative started by Terry Flotte and Parris Burd for Rare Diseases, 1998 UF made preliminary Ref
More informationAdenoviral Expression Systems. Lentivirus is not the only choice for gene delivery. Adeno-X
Adenoviral Expression Systems Lentivirus is not the only choice for gene delivery 3 Adeno-X Why choose adenoviral gene delivery? Table I: Adenoviral vs. Lentiviral Gene Delivery Lentivirus Adenovirus Infects
More informationDevelopment Stage of Therapeutic Vaccines: The Regulator s View
Development Stage of Therapeutic Vaccines: The Regulator s View Thomas Hinz Head, Section Therapeutic Vaccines Paul Ehrlich Institute, Germany thomas.hinz@pei.de 1 DISCLAIMER This is the personal views
More informationAAV-2 Helper Free Bicistronic Expression System (Hygro)
Product Manual AAV-2 Helper Free Bicistronic Expression System (Hygro) Catalog Number VPK-417-SER2 1 kit FOR RESEARCH USE ONLY Not for use in diagnostic procedures Introduction Adeno-associated viruses
More informationCalvin College Biosafety Application
SECTION 1: GENERAL INFORMATION Calvin College Biosafety Application Applicant Name: Campus Address: Email Address: Campus Phone #: Project Title: APPLICATION TYPE: Research Teaching Course #(s) PROTOCOL
More informationGene therapy. Findings by Alert
Gene therapy Published Mar 21, 2000 Version 1 Findings by Alert Research in gene therapy has increased dramatically during the past 15 years, particularly in the United States. The research has encompassed
More information510 Index. 22 rationale, 15, 16, 25 stability of complexes, 21 Atomic force microscopy (AFM), DNA conjugate particle size analysis, 41, 42
Index AAV, see Adeno-associated virus Acellular dermis, see Skin substitute Adeno-associated virus (AAV), genome structure, 446, 462 herpes simplex virus amplicons for hightiter stock production, amplicon
More informationExpectations for Biodistribution (BD) Assessments for Gene Therapy (GT) Products
Expectations for Biodistribution (BD) Assessments for Gene Therapy (GT) Products Approved by the IPRP Management Committee on 3 June 2018 12 April 2018 Table of Contents 1. Position Statement... 3 2. Executive
More informationGene Therapy: Fellow s Conference Fred Hutchinson Cancer Research Center. Zandra K. Klippel
Gene Therapy: Did we finally get it right? Fellow s Conference Fred Hutchinson Cancer Research Center University it of Washington Zandra K. Klippel March 2012 Introduction >6000 human diseases are monogenic
More informationPlasmid Features: Coordinates Feature ITR: Ad5: and hsyn1 Promoter SV40: Ampicillin:
4600 G0864 pad5hsyn1mcssv40pa Plasmid Features: 6155bp Coordinates Feature ITR: 16-118 Ad5: 16-365 and 903-3357 hsyn1 Promoter 399-862 SV40: 948-1385 Ampicillin: 5092-5952 Antibiotic Resistance: Ampicillin
More informationREGISTRATION DOCUMENT FOR RECOMBINANT & SYNTHETIC DNA RESEARCH
IBC Date Received: Reg. Doc. No.: REGISTRATION DOCUMENT FOR RECOMBINANT & SYNTHETIC DNA RESEARCH Principal Investigator: --------------------------------------- Position Title: -------------- Department:
More informationWorking Toward an Adenoviral Vector Testing Standard
Working Toward an Adenoviral Vector Testing Standard Beth Hutchins, Ph.D. Canji, Inc. Feb-01-01 1 Today s Presentation Background leading to Working Group Mission of the Adenovirus Standard Working Group
More informationAdvancing Manufacturing for Advanced Therapies
Advancing Manufacturing for Advanced Therapies Peter Marks, MD, PhD Center For Biologics Evaluation and Research, FDA CASSS Cell & Gene Therapy Symposium July 10, 2018 Overview Cell and gene therapy products
More informationCurrent Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs)
Current Considerations on Chemistry, Manufacturing and Control of Cell Therapy Products (CTPs) Wei Wei Ph.D Center for Drug Evaluation, National Medical Products Administration (CDE,NMPA) 2018/12/04 Tokyo
More informationEctopic Gene Expression in Mammalian Cells
Ectopic Gene Expression in Mammalian Cells Dr. Stefan Stein AG Grez Methodenseminar BCII Praktikum am Georg-Speyer-Haus 11.01. & 01.02.2012 1 Ectopic Gene Expression in Mammalian Cells Definition: ectopic
More informationAdeno-Associated Virus titer and aggregation characterization
Adeno-Associated Virus titer and aggregation characterization Characterization of gold-labeled Adeno-Associated Virus (AAV) and other small viruses by Nanoparticle Tracking Analysis (NTA) PARTICLE CONCENTRATION
More informationBeth Hutchins, PhD PhRMA ICH Gene Therapy Discussion Group
ICH Considerations on General Principles to Address the Risk of Inadvertent Germline Integration of Gene Therapy Vectors and Current Topics on Gene Therapy in USA Beth Hutchins, PhD PhRMA ICH Gene Therapy
More informationBiosafety Level Host Range Propagation Comments
Guidelines BSL for Commonly used Viral Vectors Version 1.0 Office of Animal Care and Institutional Biosafety (OACIB) 1737 West Polk Street (MC 672) 206 Administrative Office Building Chicago, IL 60612
More information